Lexaria Nicotine LLC’s disruptive new technology DehydraTECH™ is available to be licensed.
DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:
DehydraTECH is designed to be effective in delivering most lipophilic (i.e., fat-soluble) molecules through the human gastrointestinal system and has also demonstrated utility for transdermal applications and even effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has, or is conducting, in vitro studies, in vivo animal studies and human clinical testing, including pharmacokinetic data gathering, for the delivery of lipophilic molecules through ingestible means. Test data has consistently pointed to reduced time required to enter the bloodstream, increased quantity of absorption, and reported improvements in taste and smell of edible products.
Contact Lexaria’s President to speak about your licensing needs at [email protected].
Terms and rights associated with our licensing opportunities are discussed on an individual basis.
Lexaria’s typical approach to working with a new prospective licensee is to effect confidentiality terms and then collaborate with the license prospect under a non-binding letter of intent to evaluate the feasibility and applicability of the Lexaria DehydraTECH technology for the license prospect`s needs. Following this, if the license prospect is satisfied with the performance enhancements delivered by the DehydraTECH technology, Lexaria then seeks to transition to a definitive fee bearing agreement structure between it and the new licensee.
We will license our technology in any of the more than 40 countries around the world where the DehydraTECH is patented or patent-pending. Licensees can feel confident that Lexaria’s extensive IP portfolio will help to provide a competitive edge and protection against inferior methodologies or older, outdated technology.
Licensees should also always remember that DehydraTECH costs less than a penny per serving to implement – sometimes a bare fraction of a penny. Licensees may experience an increase in market share or an increase in pricing power as a result of offering their customers superior delivery characteristics. Customers are loyal to the improved performance of DehydraTECH based products.
We will license the DehydraTECH process to existing or new companies looking to improve delivery characteristics in the nicotine sectors.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
Reduces time of onset
In animal tests, nicotine measured in blood plasma in as little as 2 minutes.
Increases bio-absorption up to 3 – 10x, to equate or exceed that of other routes of administration like inhalational delivery.
Avoids first-pass liver metabolism
Initial testing indirectly evidences DehydraTECH may deliver molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects.